Teva terminates oral Copaxone program
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Teva is discontinuing development of an oral formulation of its multiple sclerosis therapy Copaxone (glatiramer) due to disappointing results in two pilot Phase II studies, the firm says in a March 20 filing with the Securities & Exchange Commission. The firm also had a Phase III CORAL study looking at 5 mg and 50 mg doses of oral Copaxone, but that trial also failed to produce statistically significant results. Teva "is considering future development of Copaxone in various non-parenteral formulations and will make its decision in the context of its entire MS portfolio," the firm says. Teva has rights to Ivax/Serono's Phase III oral MS agent Mylinax (cladribine) by way of its recent acquisition of Ivax...
You may also be interested in...
Tysabri Returns, But Biogen Idec’s Oral MS Drug Buy May Mean More
Of the two recent events with major implications for Biogen Idec’s multiple sclerosis franchise, the less prominent – the acquisition of Fumapharm, its partner on the experimental oral MS therapeutic BG-12 – could, in the long run, be more significant than the re-approval of Tysabri.
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.